Dec 23 |
Propolis for COVID-19: real-time meta analysis of 3 studies | |
| Significantly lower risk is seen for hospitalization and recovery. 3 studies from 2 independent teams in 2 countries show significant benefit. Meta analysis using the most serious outcome reported shows 41% [-13‑69%] lower risk.. | ||
Nov 27 |
et al., Bioresources and Bioprocessing, doi:10.1186/s40643-024-00822-z | Assessing multi-target antiviral and antioxidant activities of natural compounds against SARS-CoV-2: an integrated in vitro and in silico study |
| In Vitro and In Silico study showing that propolis, curcumin, quercetin, and ginseng compounds inhibit SARS-CoV-2 infection and bind to key viral proteins. In Vero CCL-81 cells, propolis and curcumin significantly reduced SARS-CoV-2 viral.. | ||
Nov 22 |
et al., Chemistry & Biodiversity, doi:10.1002/cbdv.202401947 | Uncovering the Therapeutic Potential of Propolis Extract in Managing Hyperinflammation and Long COVID‐19: A Comprehensive Bioinformatics Study |
| In Silico study showing that propolis extract may be beneficial for COVID-19. Authors used network pharmacology and bioinformatics to identify 25 inflammation-associated targets relevant to COVID-19, including STAT1, NOS2, and BTK, throug.. | ||
Aug 13 |
et al., Journal of Chromatography A, doi:10.1016/j.chroma.2024.465265 | Countercurrent chromatography isolation of green propolis biomarkers: potential blockers of SARS-CoV-2 RBD and ACE2 interaction |
| In Vitro study showing potential inhibition of SARS-CoV-2 spike protein and ACE2 interaction by artepillin C and baccharin from Brazilian green propolis. Artepillin C showed 67.3% inhibition of Spike:ACE2 interaction at 10 μM, while bacch.. | ||
Apr 5 |
et al., Pharmaceuticals, doi:10.3390/ph17040463 | Potential Anti-Inflammatory and Anti-Fatigue Effects of an Oral Food Supplement in Long COVID Patients |
| RCT of 33 long COVID outpatients showing anti-inflammatory and anti-fatigue effects with treatment based on Echinacea angustifolia, rosehip, propolis, royal jelly, and zinc. The treatment significantly reduced inflammatory biomarkers like.. | ||
Jan 26 |
et al., ADMET and DMPK, doi:10.5599/admet.2128 | New insights of propolis nanoformulation and its therapeutic potential in human diseases |
| Review of propolis nanoformulations and their therapeutic potential in various human diseases. Authors provide an overview of the chemical composition and biological activities of propolis, noting challenges such as poor bioavailability a.. | ||
Jan 22 |
et al., BIO Web of Conferences, doi:10.1051/bioconf/20248800007 | Exploring Therapeutic Potential of Nutraceutical Compounds from Propolis on MAPK1 Protein Using Bioinformatics Approaches as Anti-Coronavirus Disease 2019 (COVID-19) |
| In Silico study suggesting that propolis compounds broussoflavonol F, glyasperin A, and sulabiroins A may inhibit SARS-CoV-2 by targeting the MAPK1 protein. Using network pharmacology, authors identified 74 overlapping targets between pro.. | ||
Nov 22 2023 |
et al., Phytotherapy Research, doi:10.1002/ptr.8047 | The influence of propolis plus Hyoscyamus niger L. against COVID‐19: A phase II, multicenter, placebo‐controlled, randomized trial |
| 86% lower mortality (p=0.24), 86% lower ICU admission (p=0.06), and 64% improved recovery (p=0.007). RCT 140 patients showing lower progression and improved recovery with propolis plus Hyoscyamus niger L.syrup. | ||
Oct 27 2023 |
et al., Scientific Reports, doi:10.1038/s41598-023-43764-w | Standardized Brazilian green propolis extract (EPP-AF®) in COVID-19 outcomes: a randomized double-blind placebo-controlled trial |
| 22% lower ventilation (p=0.54), 11% lower ICU admission (p=0.65), 16% shorter hospitalization (p=0.19), and 68% improvement (p=0.02). RCT 188 patients in Brazil, showing shorter hospitalization and improved outcomes with propolis, but without statistical significance. The incidence of secondary infections was significantly lower in the treatment group. | ||
Aug 31 2023 |
et al., In Vivo, doi:10.21873/invivo.13313 | A Prospective Study of AFree Oral Spray as an Adjuvant Therapy for Mild and Moderate COVID-19 in Community Health Stations: Clinical Progression and Viral Clearance Outcomes |
| RCT 1,252 mild/moderate COVID-19 patients Vietnam, showing faster recovery and faster viral clearance with an oral spray containing zinc, propolis, xylitol, ginger, and DMSO. 5-10 times per day. | ||
Jun 27 2023 |
et al., In Vivo, doi:10.21873/invivo.13262 | Therapeutic Efficacy of AFree Oral Spray on the Symptoms and Course of Moderate and Severe COVID-19 in the Field Hospital |
| 84% improved recovery (p<0.0001) and 78% improved viral clearance (p=0.06). RCT 200 hospitalized patients in Vietnam, showing faster recovery with an oral spray containing zinc, propolis, xylitol, ginger, and DMSO. | ||
Apr 30 2023 |
et al., Journal of Functional Foods, doi:10.1016/j.jff.2023.105544 | Chewable tablet with herbal extracts and propolis arrests Wuhan and Omicron variants of SARS-CoV-2 virus |
| In Vitro study showing that a chewable tablet containing green tea, bilberry, pomegranate peel, and propolis extracts inhibited SARS-CoV-2 Wuhan and omicron variants in Vero E6 cells. The tablet at 110μg/mL eliminated viral activity for b.. | ||
Jan 1 2023 |
et al., Molecules, doi:10.3390/molecules28010359 | The Effects of Propolis on Viral Respiratory Diseases |
| Review of the antiviral effects of propolis against respiratory viruses including SARS-CoV-2, influenza, parainfluenza, and rhinoviruses. Authors note that propolis extracts have shown activity against these viruses through mechanisms lik.. | ||
Sep 19 2022 |
et al., Molecules, doi:10.3390/molecules27186120 | Propolis: Its Role and Efficacy in Human Health and Diseases |
| Review of propolis for health and diseases including COVID-19. Propolis contains many bioactive compounds like flavonoids, phenolic acids, and terpenes that have exhibited antiviral, anti-inflammatory, and immunomodulatory properties in s.. | ||
Mar 31 2022 |
et al., Journal of Integrative Medicine, doi:10.1016/j.joim.2022.01.008 | Potential effects of propolis and honey in COVID-19 prevention and treatment: A systematic review of in silico and clinical studies |
| Review of potential effects of propolis and honey in COVID-19 prevention and treatment. Authors systematically reviewed in silico and clinical studies on propolis or bee products against SARS-CoV-2. In silico studies showed compounds like.. | ||
Feb 28 2022 |
et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2021.112595 | The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review |
| Review of the potential therapeutic benefits of propolis in treating respiratory tract-related diseases and disorders. Authors overview extensive in vitro, in silico, animal, and human clinical trial evidence demonstrating antiviral, anti.. | ||
Oct 21 2021 |
et al., European Review for Medical and Pharmacological Sciences, doi:10.26355/eurrev_202212_30483 (date from preprint) | The prophylactic efficacy of Anatolian propolis in individuals at high risk of COVID-19 |
| 86% fewer cases (p=0.003). Prospective study of 204 high-risk healthcare professionals showing significantly lower COVID-19 infection with prophylactic use of Anatolian propolis drops over one month. The treatment group received 20 drops of 30% Anatolian propolis e.. | ||
Jun 30 2021 |
et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2021.111526 | Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial |
| 62% lower ventilation (p=0.19), 24% lower ICU admission (p=0.73), and 35% shorter hospitalization (p=0.001). RCT 124 hospitalized COVID-19 patients in Brazil. The treatment groups received standardized green propolis extract (EPP-AF) at doses of 400mg/day or 800mg/day for 7 days, in addition to standard care. The EPP-AF groups had significantly .. | ||
Apr 15 2021 |
et al., Phytotherapy Research, doi:10.1002/ptr.7116 | The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID‐19: A clinical trial |
| Randomized clinical trial of 50 outpatients with suspected COVID-19 showing improvement in symptoms such as cough, shortness of breath, sore throat, and chest pain with a syrup containing propolis and Hyoscyamus niger L. methanolic extrac.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.